Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 71Active not recruiting 31Not yet recruiting 22Completed 12Terminated 6Suspended 2Withdrawn 1Enrolling by invitation 1Approved for marketing 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Eyelid Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 31Magnetic Resonance Spectroscopy 19Biopsy 16Cyclophosphamide 10venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Vincristine 5Etoposide 5fludarabine phosphate 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiation 4Injections 4Doxorubicin 4Cisplatin 4fludarabine 3X-Rays 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Radiosurgery 3Prednisone 3Leucovorin 3Irinotecan 3Ipilimumab 3Fluorouracil 3Educational Status 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × cemiplimab × 1 year × Clear all
NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Duke University

Phase 2 Suspended
126 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡